DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for generalized anxiety disorder — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeneralized anxiety disorder maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for generalized anxiety disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopamine receptor D2 (DRD2) — DRD2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 8alphadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9BS9 · 2.28 Å · ligand (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide (7LD). Experimental structure, not a prediction.
What the evidence adds up to
Generalised anxiety disorder is described as a fairly chronic condition with significant long-term distress and comorbidity. Research has concentrated on short-term treatment, and long-term outcome studies after either short- or long-term treatment have been relatively neglected. The benefits and risks of various drug and nondrug therapies for long-term management are discussed, but no specific drug is named in the abstract, and no numerical data on efficacy or survival are provided.
In controlled outcome studies of behavioural psychotherapy for generalised anxiety disorder, the most encouraging results come from treatments that combine cognitive and behavioural techniques and are presented within a structured self-help framework. However, questions remain about which components of therapy are important and what the mechanisms of change are. A definitive conclusion about the overall effectiveness of behavioural psychotherapy is precluded by an absence of long-term follow-up and other methodological problems.
An overview of pharmacological treatment for anxiety disorders, including generalised anxiety disorder, notes that substantial advances have been made in identifying and treating these conditions. The evidence for efficacy of various pharmacological agents, including relevant oral dosing and plasma-level data, is discussed, along with the disadvantages of medication treatment. No specific drug, response rate, or sample size is given in this abstract.
A chapter reviewing six randomised clinical trials that contributed significantly to the pharmacotherapy of anxiety and related disorders, including generalised anxiety disorder, discusses early and ongoing challenges and key advances. The chapter closes by considering future directions, but again no specific drug, numerical outcome, or trial result is reported in the abstract. What is still missing from the literature as presented here are long-term follow-up data, definitive identification of effective treatment components, and adequately powered, well-designed trials that can provide concrete numerical evidence of efficacy for any specific pharmacological or psychotherapeutic intervention in generalised anxiety disorder.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Psychopharmacology · 1990 · 87 citations
The Clinical Course and Long-Term Management of Generalized Anxiety Disorder
AbstractEvidence suggests that generalized anxiety disorder (GAD) has a fairly chronic course marked by significant long-term distress and comorbidity. Research has focused on short-term treatment of GAD, and long-term outcome studies after either short- or long-term treatment have been relatively neglected. The authors discuss the benefits and risks of various drug and nondrug therapies used in the long-term management of generalized anxiety disorder and suggest avenues for future research.
Journal of Consulting and Clinical Psychology · 1996 · 82 citations
Recent developments in the psychopharmacology of anxiety disorders.
AbstractAnxiety disorders are the most prevalent mental disorders in the United States. In the past 3 decades, substantial advances have been made in the ability to identify and treat anxiety disorders including panic disorder (PD), social phobia (SP), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). It is now known that these common, usually chronic disorders confer significant disability to untreated sufferers. This overview highlights some of the important advances in pharmacological treatment of anxiety disorders. Evidence for efficacy of the various pharmacological agents (including relevant oral dosing and plasma-level data) and of acute and long-term treatment, and the disadvantages of medication treatment are discussed. Finally, some important clinical questions remaining to be addressed by psychopharmacological research are reviewed.
International Review of Psychiatry · 1989 · 5 citations
Behavioural Psychotherapy for Generalized Anxiety Disorder
AbstractIn controlled outcome studies of behavioural psychotherapy for generalized anxiety disorder the most encouraging results to date are from treatments which combine cognitive and behavioural techniques and where treatment is presented within a structured self-help framework. Questions remain however, as to which components of therapy are important and what the mechanisms of change are. A definitive conclusion about the overall effectiveness of behavioural psychotherapy for generalized anxiety disorder is precluded by a number of methodological problems, including an absence of long term follow-up.
Oxford University Press eBooks · 2020 · 0 citations
Pharmacotherapy of anxiety and related disorders
AbstractAnxiety disorders are the most prevalent of the mental disorders, and good translational models of these conditions encourage pharmacotherapy studies. This chapter discusses six randomized clinical trials that have contributed significantly to the pharmacotherapy of anxiety and related disorders, including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and social anxiety disorder. Although any such list is necessarily incomplete, these selections may shed light on early and ongoing challenges in the field and on key advances to date. After reviewing these foundational papers, the advances they represent, and the work that they have given impetus to, the chapter closes by considering future directions in work on the pharmacotherapy of anxiety and related disorders.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
